Hua Medicine (Shanghai) Ltd.

Many of China’s homegrown first-in-class drugs have had a hard time becoming rainmakers for their originators, with few becoming blockbusters in domestic or international sales terms. Since the first

Bayer’s best hope of reclaiming its past dominance in China’s oral diabetes drug market has collapsed. The German major’s setback in the space, packed with low-priced competitors, came as local partne

Hua Medicine (Shanghai) Ltd. obtained the first approval globally for its novel diabetes drug Huatangning (dorzagliatin) in China last September and soon launched it to market. Roughly eight months l

Shanghai’s biopharma sector is experiencing a resounding recovery after being struck by spikes of COVID-19 cases in the first half of this year. Original innovation incubated by a consortium establish